Schizophrenia—an overview

RA McCutcheon, TR Marques, OD Howes - JAMA psychiatry, 2020 - jamanetwork.com
Importance Schizophrenia is a common, severe mental illness that most clinicians will
encounter regularly during their practice. This report provides an overview of the clinical …

The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research

SG Potkin, JM Kane, CU Correll, JP Lindenmayer… - NPJ …, 2020 - nature.com
Abstract Treatment-resistant schizophrenia (TRS), the persistence of positive symptoms
despite≥ 2 trials of adequate dose and duration of antipsychotic medication with …

Dopamine and glutamate in schizophrenia: biology, symptoms and treatment

RA McCutcheon, JH Krystal, OD Howes - World Psychiatry, 2020 - Wiley Online Library
Glutamate and dopamine systems play distinct roles in terms of neuronal signalling, yet both
have been proposed to contribute significantly to the pathophysiology of schizophrenia. In …

Economics and mental health: the current scenario

M Knapp, G Wong - World Psychiatry, 2020 - Wiley Online Library
Economics and mental health are intertwined. Apart from the accumulating evidence of the
huge economic impacts of mental ill‐health, and the growing recognition of the effects that …

A guideline and checklist for initiating and managing clozapine treatment in patients with treatment-resistant schizophrenia

CU Correll, O Agid, B Crespo-Facorro… - CNS drugs, 2022 - Springer
Abstract Treatment-resistant schizophrenia (TRS) will affect about one in three patients with
schizophrenia. Clozapine is the only treatment approved for TRS, and patients should be …

Two distinct neuroanatomical subtypes of schizophrenia revealed using machine learning

GB Chand, DB Dwyer, G Erus, A Sotiras, E Varol… - Brain, 2020 - academic.oup.com
Neurobiological heterogeneity in schizophrenia is poorly understood and confounds current
analyses. We investigated neuroanatomical subtypes in a multi-institutional multi-ethnic …

[HTML][HTML] Clinical guidance on the identification and management of treatment-resistant schizophrenia

JM Kane, O Agid, ML Baldwin… - The Journal of …, 2019 - legacy.psychiatrist.com
Treatment-resistant schizophrenia (TRS) occurs in approximately 30% of individuals
diagnosed with schizophrenia. The identification and management of TRS in clinical …

Guidelines for the pharmacotherapy of schizophrenia in adults

G Remington, D Addington, W Honer… - The Canadian …, 2017 - journals.sagepub.com
Objective: The present guidelines address the pharmacotherapy of schizophrenia in adults
across different stages, phases, and symptom domains. Method: Guidelines were developed …

Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats

EC Onwordi, EF Halff, T Whitehurst, A Mansur… - Nature …, 2020 - nature.com
Synaptic dysfunction is hypothesised to play a key role in schizophrenia pathogenesis, but
this has not been tested directly in vivo. Here, we investigated synaptic vesicle glycoprotein …

[HTML][HTML] Cognitive dysfunction in schizophrenia: an expert group paper on the current state of the art

PD Harvey, M Bosia, R Cavallaro, OD Howes… - Schizophrenia Research …, 2022 - Elsevier
Cognitive impairment in schizophrenia represents one of the main obstacles to clinical and
functional recovery. This expert group paper brings together experts in schizophrenia …